Search company, investor...

Predict your next investment

Allergan company logo
Corporation
HEALTHCARE | Drug Development
allergan.com

Investments

3

Portfolio Exits

3

Partners & Customers

10

Service Providers

2

About Allergan

Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. On June 25, 2019, Allergan was acquired by AbbVie.

Headquarters Location

Clonshaugh Business and Technology Park Coolock

Dublin, D17 E400,

Ireland

862-261-7000

Want to inform investors similar to Allergan about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Allergan

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Allergan in 4 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

D

Diabetes

1,903 items

M

Medical Devices

3,607 items

Companies that received FDA De Novo clearances since 2010. Companies tagged as #FDADeNovos

Latest Allergan News

Intravitreal Injectables Global Market Report 2022: Featuring Allergan, Bristol-Myers Squibb, Novartis, F.Hoffman-La Roche & More

Jan 26, 2023

News provided by Share this article Share this article Industry Outlook The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2022 to 2030. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment. Rising prevalence of diabetes and increasing geriatric population drive growth As per the research citing of the Lancet journal the global prevalence rate of any age related macular degeneration is 8.69% with a higher prevalence rate in the Caucasian population followed by mongoloids. The primary factors that increase the risk factor for occurrence of macular degeneration are increasing geriatric population, smoking, obesity, genetic, diabetes etc. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people having previous history of diabetes. Endophthalmitis is growing at faster rate owing to rise in air and water pollution and eye trauma. Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market Anti-VEGF is dominating the drug class segment for Intravitreal injections market. Since its commercialization in 2006 drugs such as bevacizumab (Avastin), ranibizumab (Lucentis) etc. are considered as the first line drug therapy in patients suffering with neovascular age related macular degeneration and ocular vein occlusion. Its inherent features such as excellent biocompatibility and impressive pharmacodynamic properties has led to its increased popularity among ophthalmologist worldwide. Corticosteroids are used as an adjuvant drug therapy in alleviating inflammation caused due to eye infections. Antifungal drugs and antibiotics together are prescribed in eye infections such as endophthalmitis and retinitis. Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffering with low vision. Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America. Europe represents 26% share on account of the presence of thriving healthcare infrastructure and domicile of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F.Hoffman-La Roche Ltd. etc. propel the market growth in Europe. Asia Pacific is holding 20% market share and is keen to capture the regional market in the near future on account of supportive regulatory environment provided by healthcare agencies and developing ophthalmic research centers providing optimum eye care. Pharmaceutical giants competing to maintain stronghold in intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc. Market Segmentation Key questions answered in this report What are the key micro and macro environmental factors that are impacting the growth of Intravitreal Injectables market? What are the key investment pockets with respect to product segments and geographies currently and during the forecast period? Estimated forecast and market projections up to 2030. Which segment accounts for the fastest CAGR during the forecast period? Which market segment holds a larger market share and why? Are low and middle-income economies investing in the Intravitreal Injectables market? Which is the largest regional market for Intravitreal Injectables market? What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa? Which are the key trends driving Intravitreal Injectables market growth? Who are the key competitors and what are their key strategies to enhance their market presence in the Intravitreal Injectables market worldwide? Key Topics Covered:

Allergan Investments

3 Investments

Allergan has made 3 investments. Their latest investment was in Stemson Therapeutics as part of their Seed VC on September 9, 2020.

CBI Logo

Allergan Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/16/2020

Seed VC

Stemson Therapeutics

$7.5M

Yes

2

1/10/2017

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

10/14/2010

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

9/16/2020

1/10/2017

10/14/2010

Round

Seed VC

Series A - II

Series C

Company

Stemson Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$7.5M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

0

Allergan Portfolio Exits

3 Portfolio Exits

Allergan has 3 portfolio exits. Their latest portfolio exit was Anda on August 02, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/2/2016

Divestiture

Anda

$99M

4

2/16/2015

Acq - Fin - II

Subscribe to see more

$99M

Subscribe to see more

10

10/23/2012

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

0

Date

8/2/2016

2/16/2015

10/23/2012

Exit

Divestiture

Acq - Fin - II

Corporate Majority

Companies

Anda

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

10

0

Allergan Acquisitions

37 Acquisitions

Allergan acquired 37 companies. Their latest acquisition was Luminera - Dermal Filler Business on October 07, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/7/2020

$99M

Acquired Unit

1

3/26/2019

Private Equity

$99M

Acquired

1

9/14/2018

Series C

$99M

$38.04M

Acquired

1

2/7/2018

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/13/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/7/2020

3/26/2019

9/14/2018

2/7/2018

12/13/2017

Investment Stage

Private Equity

Series C

Grant

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$38.04M

$99M

Note

Acquired Unit

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Allergan Partners & Customers

10 Partners and customers

Allergan has 10 strategic partners and customers. Allergan recently partnered with Eurobio Scientific on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/6/2021

Licensor

France

Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan

Hervé Duchesne de Lamotte , Deputy General Manager of Eurobio Scientific says : `` Eurobio Scientific 's therapeutics program lives on , thanks to its longtime partner Allergan .

1

1/5/2021

Licensor

Japan

Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs

We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies .

3

6/18/2020

Licensor

United States

AbbVie nixes microbiome GI program collaboration with Assembly Biosciences

Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 .

1

5/8/2020

Partner

China

Subscribe to see more

Subscribe to see more

10

3/4/2020

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

10/6/2021

1/5/2021

6/18/2020

5/8/2020

3/4/2020

Type

Licensor

Licensor

Licensor

Partner

Licensor

Business Partner

Country

France

Japan

United States

China

United States

News Snippet

Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan

Hervé Duchesne de Lamotte , Deputy General Manager of Eurobio Scientific says : `` Eurobio Scientific 's therapeutics program lives on , thanks to its longtime partner Allergan .

Sosei Heptares To Regain Worldwide Rights To Muscarinic Agonist Programs

We have established partnerships with some of the world 's leading pharmaceutical companies , including AbbVie , AstraZeneca , Biohaven , Genentech , GSK , Novartis , Pfizer and Takeda and additionally with multiple emerging technology companies .

AbbVie nixes microbiome GI program collaboration with Assembly Biosciences

Assembly Biosciences announces that it has regained global rights to all microbiome gastrointestinal programs out-licensed to AbbVie unit Allergan in January 2017 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

Allergan Service Providers

2 Service Providers

Allergan has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Allergan Team

56 Team Members

Allergan has 56 team members, including current Senior Vice President, Carrie Strom.

Name

Work History

Title

Status

Carrie Strom

Senior Vice President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Carrie Strom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Senior Vice President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Allergan to Competitors

H
Healios

Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice. Healios was founded in 2012 and is based in Basel, Switzerland.

I
Immunwork

Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.

Sumitovant Logo
Sumitovant

Sumitovant is a biopharmaceutical group focused on improving drug development. The company offers a tech-enabled approach to drug discovery, development and commercialization. It was founded in New York, New York.

Binx Health Logo
Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Vivante Health Logo
Vivante Health

Vivante Health offers an all-in-one digital program for digestive health and disease. GIThrive is its multidisciplinary program that brings together, in one place, everything necessary to manage gut trouble. GIThrive is an employer- and health plan-sponsored digestive health program featuring personalized nutrition plans, daily health challenges, "Med-ucation" to encourage prescription adherence, and on-demand care to address symptom flares and pain with 24/7 Gut-Side Assistance. It was founded in 2016 and is based in Chicago, Illinois.

Ybrain Logo
Ybrain

Ybrain is a brain science healthcare company that commercializes home-based neuropsychiatry diagnosis, treatment, and management solutions for people with mental illnesses. The company's products include MINDD STIM, a medical-grade, noninvasive brain stimulation system that uses weak currents to stimulate the human brain and help patients suffering from mental health conditions such as depression; and MINDD SCAN, a wireless EEG system that allows operators to quickly complete preparation and collection of EEG signals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.